PharmaMar Submits Marketing Authorization Application In Europe For Yondelis(R) In Soft Tissue Sarcoma
PharmaMar today announces the submission
of a Marketing Authorization Application to the European Medicines
Agency (EMEA) for Yondelis(R) (trabectedin) as a treatment for soft
tissue sarcomas (STS). The application is based on the results of a
randomised, Phase II pivotal study of Yondelis, known as STS-201.